Stevia, a natural sweetener derived from the Stevia rebaudiana plant, has become increasingly popular in the UK as a calorie-free alternative to sugar. Approved for use as food additive E960, it is widely consumed by people managing diabetes, weight, or simply seeking to reduce sugar intake. However, with rising awareness of non-alcoholic fatty liver disease (NAFLD)—a condition affecting up to 30% of UK adults—some consumers have questioned whether stevia might contribute to liver fat accumulation. This article examines the evidence on whether stevia causes fatty liver, reviews current UK regulatory guidance, and provides practical advice for safe use.

What Is Stevia and How Is It Used?

Stevia is a natural, non-nutritive sweetener derived from the leaves of Stevia rebaudiana, a plant native to South America. The sweet compounds in stevia, known as steviol glycosides, are approximately 200–300 times sweeter than sucrose (table sugar), yet they contain virtually no calories. This makes stevia an attractive alternative for individuals seeking to reduce sugar intake, manage weight, or control blood glucose levels.

In the United Kingdom, stevia-based sweeteners are widely available in supermarkets, health food shops, and online retailers. They are sold in various forms, including:

• Powdered extracts for use in hot beverages and baking

• Liquid drops for precise dosing in drinks and recipes

• Granulated blends that mimic the texture of sugar (note that some blends contain bulking agents such as maltodextrin, which may contribute small amounts of calories and affect blood glucose)

• Pre-sweetened products such as soft drinks, yoghurts, and confectionery

Purified steviol glycosides are approved for use as food additives in Great Britain under the designation E960. In Great Britain, food additives are regulated by the Food Standards Agency (and Food Standards Scotland), in accordance with retained and assimilated EU legislation. The European Food Safety Authority (EFSA) established an acceptable daily intake (ADI) of 4 milligrams per kilogram of body weight per day, expressed as steviol equivalents, following comprehensive safety assessments in 2010 and subsequent reviews. For a 70-kilogram adult, this equates to approximately 280 milligrams daily. Most consumers fall well below this level, though some high-consuming groups—particularly children who consume multiple stevia-sweetened products—may approach the ADI. The ADI represents a lifetime average with a substantial safety margin, and occasional exceedance is not a cause for concern.

It is important to note that the authorisation applies to purified steviol glycosides (E960), not to unrefined stevia leaf or crude extracts, which are not authorised as food additives in the UK.

Stevia is particularly popular among people with type 2 diabetes, those following calorie-restricted diets, and individuals wishing to reduce their consumption of artificial sweeteners such as aspartame or saccharin. Unlike sugar, stevia does not raise blood glucose levels, making it a suitable option for glycaemic control. However, as with any dietary component, understanding its safety profile—including any potential effects on liver health—is essential for informed decision-making.

Understanding Fatty Liver Disease: Causes and Risk Factors

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. The condition is broadly classified into two categories: alcoholic fatty liver disease (AFLD), caused by excessive alcohol consumption, and non-alcoholic fatty liver disease (NAFLD), which develops in individuals who drink little or no alcohol. (Note: emerging international nomenclature uses the term metabolic dysfunction-associated steatotic liver disease [MASLD], though NICE guidance continues to use NAFLD.) NAFLD is increasingly common in the UK, affecting an estimated 20–30% of the general population.

The primary risk factors for NAFLD include:

• Obesity and overweight, particularly central adiposity

• Type 2 diabetes mellitus and insulin resistance

• Dyslipidaemia, including elevated triglycerides and low HDL cholesterol

• Metabolic syndrome, a cluster of cardiovascular risk factors

• Sedentary lifestyle and poor dietary habits

NAFLD exists on a spectrum. Simple steatosis (fat accumulation alone) is generally benign, but it can progress to non-alcoholic steatohepatitis (NASH), characterised by inflammation and liver cell damage. Over time, NASH may lead to fibrosis, cirrhosis, and even hepatocellular carcinoma.

According to NICE guidance (NG49), there is no population screening programme for NAFLD, but individuals with risk factors should be assessed using non-invasive methods. The recommended first-line approach is to calculate a FIB-4 score or NAFLD Fibrosis Score to stratify the risk of advanced fibrosis. For adults under 65 years, a FIB-4 score below 1.3 suggests low risk, whilst a score above 2.67 suggests higher risk. For those aged 65 and over, thresholds are adjusted (low risk <2.0; higher risk >3.25). If the score is indeterminate or high, an Enhanced Liver Fibrosis (ELF) test and/or transient elastography (FibroScan) should be arranged. Individuals with high-risk results should be referred to hepatology services. It is important to note that liver function tests (LFTs) can be normal in NAFLD, and ultrasound is not a screening tool for the condition.

Diet plays a crucial role in both the development and management of fatty liver disease. Excessive consumption of refined carbohydrates, particularly fructose from sugar-sweetened beverages, has been strongly linked to NAFLD. Conversely, weight loss of 7–10% of body weight can significantly reduce hepatic fat content and improve liver inflammation. Understanding these mechanisms is important when evaluating whether sugar substitutes like stevia might influence liver health, either beneficially or adversely.

Safe Use of Stevia: Guidance for UK Consumers

In Great Britain, steviol glycosides (E960) are authorised food additives regulated by the Food Standards Agency (and Food Standards Scotland), in accordance with retained and assimilated European Union legislation. Steviol glycosides have undergone rigorous safety assessments and are approved for use in a wide range of food and beverage products.

The European Food Safety Authority (EFSA) conducted comprehensive toxicological evaluations of steviol glycosides in 2010, with subsequent updates confirming their safety. These assessments examined potential effects on multiple organ systems, including the liver, kidneys, cardiovascular system, and reproductive organs. No adverse effects were observed at doses well above typical human consumption levels. The established acceptable daily intake (ADI) of 4 mg/kg body weight per day (expressed as steviol equivalents) provides a substantial safety margin.

For most individuals, stevia is well tolerated with minimal side effects. Occasionally, some people report:

• Mild gastrointestinal symptoms such as bloating or nausea

• A bitter or liquorice-like aftertaste, particularly with certain steviol glycoside preparations

Allergic reactions to purified steviol glycosides are extremely rare, as the purification process removes virtually all plant proteins. If you suspect any adverse reaction to a food product containing stevia, you may report it via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk) or the Food Standards Agency's 'Report a food problem' service.

The NHS does not issue specific warnings against stevia consumption for the general population. However, as with any dietary modification, individuals with pre-existing medical conditions—particularly liver disease, diabetes, or cardiovascular disorders—should consult their GP or a registered dietitian before making significant changes to their sweetener use.

Some small, short-term studies have suggested that stevia may have mild effects on blood pressure or blood glucose levels, but these effects are generally not clinically significant at typical dietary intakes. Patients taking medications for blood pressure or blood glucose control do not usually require additional monitoring solely due to stevia consumption, though those using very large amounts or with specific clinical concerns should discuss this with their healthcare provider. Regular monitoring and professional guidance ensure safe integration of stevia into the diet, particularly for those with complex medical needs.

Does Stevia Cause Fatty Liver? Examining the Evidence

There is no credible scientific evidence suggesting that stevia causes fatty liver disease. Comprehensive safety assessments by the European Food Safety Authority (EFSA), including toxicological studies and reviews of human data, have found no evidence of hepatotoxicity or adverse effects on liver function associated with steviol glycosides at typical consumption levels.

Several animal studies have investigated stevia's effects on hepatic metabolism. Research published in peer-reviewed journals has demonstrated that steviol glycosides do not accumulate in the liver and are efficiently metabolised and excreted. Some experimental studies in rodent models of metabolic syndrome have shown that stevia supplementation may:

• Reduce hepatic lipid accumulation compared to sugar-fed controls

• Improve markers of liver inflammation and oxidative stress

• Enhance insulin sensitivity, which indirectly benefits liver health

• Lower serum triglycerides, a risk factor for NAFLD

It is important to note that these findings are from preclinical (animal) studies. Human clinical trials, whilst more limited in number, duration, and size, have not identified hepatotoxicity or increased liver fat associated with stevia consumption. Systematic reviews of stevia's safety profile have found no evidence of adverse hepatic effects in studies involving diabetic patients, obese individuals, or healthy volunteers consuming stevia regularly. However, the human evidence base remains modest and largely short-term, so long-term effects continue to be monitored.

It is important to distinguish between stevia itself and the context in which it is consumed. Some commercially available products containing stevia may also include other ingredients—such as sugar alcohols, bulking agents, or in the case of processed foods, unhealthy fats and refined carbohydrates—that could theoretically contribute to metabolic dysfunction if consumed excessively.

For individuals concerned about liver health, replacing sugar-sweetened beverages and foods with stevia-sweetened alternatives may be beneficial as part of a broader strategy to reduce caloric intake, achieve weight loss, and improve diet quality. UK-relevant systematic reviews support the role of low- and no-calorie sweeteners in reducing energy intake when substituted for sugar. However, stevia is not a treatment for existing fatty liver disease.

Management of NAFLD, as outlined in NICE guideline NG49, requires a comprehensive approach including:

• Weight reduction of 7–10% of body weight through calorie restriction and increased physical activity

• Dietary modification emphasising whole foods, vegetables, lean proteins, and healthy fats

• Avoidance of alcohol and hepatotoxic substances

• Management of comorbidities such as diabetes and dyslipidaemia

Patients with diagnosed fatty liver disease or abnormal liver function tests should discuss dietary changes, including sweetener choices, with their GP or hepatology specialist. If you experience symptoms such as persistent abdominal discomfort, jaundice (yellowing of skin or eyes), dark urine, unusual fatigue, confusion, or signs of gastrointestinal bleeding, seek medical attention promptly. Depending on severity, contact your GP, call NHS 111, or attend an emergency department. These symptoms may indicate liver dysfunction requiring investigation—though such symptoms would not be expected from stevia consumption alone.

Frequently Asked Questions